RE: NASH29 Aug 2020 21:48
16/7/20
Potential Investigator-Led Clinical Collaborations
Guy's and St Thomas' NHS Foundation Trust
"We are working with patient groups to plan a grant application for a Phase II clinical trial programme on SFX-01 in children with ASD, hoping to recruit from a consortium of UK hospitals.
Our interest, and that of the parents of some children with ASD, was first triggered when a small clinical study showed that sulforaphane helped improve quality of life in autistic young people.
Our end goal is improving the range of treatment options available for autistic young people, in order to improve quality of life and independence.
” Dr Michael Absoud, a consultantin paediatric neurodisability"We are delighted that Evgenwill support our plans to undertake a clinical trial on SFX-01 in patients with NASH. Oxidative stress is pivotal to the development of NASH and our research suggests that activation of the Nrf2 pathway, which in turn reduces oxidative stress, can reverse the pathology.
University of Dundee
”John Dillon,Professor of Hepatology and Gastrenterology, University of Dundee's the School of Medicine "We are pleased that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with CKD.
University of Rochester- New York
Increased oxidative stress is a major molecular underpinning of CKD progression and our research suggests that patients with the GSTM1 null allele may particularly benefit from sulforaphane treatment via SFX-01 dosing.’’ Thu Le, Professor of Medicine and Chief of the Division of Nephrology at the University of Rochester Medical Center, New York.
Sign In
Follow the stocks
